Analysis of serum B cell‐activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosus

To determine the presence and clinical associations of the soluble receptors of B cell‐activating factor from the tumor necrosis factor family (BAFF) in serum of patients with systemic lupus erythematosus (SLE).

[1]  Systemic Lupus Erythematosus Disease Activity Index , 2020, Definitions.

[2]  F. Vincent,et al.  Effect of storage duration on cytokine stability in human serum and plasma , 2019, Cytokine.

[3]  P. López,et al.  Profiling of B-Cell Factors and Their Decoy Receptors in Rheumatoid Arthritis: Association With Clinical Features and Treatment Outcomes , 2018, Front. Immunol..

[4]  F. Vincent,et al.  Analysis of Serum Interleukin (IL)-1β and IL-18 in Systemic Lupus Erythematosus , 2018, Front. Immunol..

[5]  R. Hohlfeld,et al.  Human Plasmacytoid Dendritic Cells Display and Shed B Cell Maturation Antigen upon TLR Engagement , 2017, The Journal of Immunology.

[6]  E. Morand,et al.  Clinical associations of IL-10 and IL-37 in systemic lupus erythematosus , 2016, Scientific Reports.

[7]  T. Olsson,et al.  γ-secretase directly sheds the survival receptor BCMA from plasma cells , 2015, Nature Communications.

[8]  K. Berer,et al.  This information is current as Activation in Autoimmunity Released by ADAM 10 and Reflects B Cell The Immunoregulator Soluble TACI Is Lichtenthaler and , 2014 .

[9]  M. Angelopoulou,et al.  Serum Soluble TACI, a BLyS Receptor, Is a Powerful Prognostic Marker of Outcome in Chronic Lymphocytic Leukemia , 2014, BioMed research international.

[10]  P. Schneider,et al.  The BAFF/APRIL system in SLE pathogenesis , 2014, Nature Reviews Rheumatology.

[11]  D. Isenberg,et al.  Systemic lupus erythematosus , 1956, The Lancet.

[12]  D. Isenberg,et al.  Elevated serum BAFF levels are associated with rising anti-double-stranded DNA antibody levels and disease flare following B cell depletion therapy in systemic lupus erythematosus. , 2013, Arthritis and rheumatism.

[13]  T. Dörner,et al.  Immunopathogenic mechanisms of systemic autoimmune disease , 2013, The Lancet.

[14]  F. Mackay,et al.  Clinical associations of serum interleukin-17 in systemic lupus erythematosus , 2013, Arthritis Research & Therapy.

[15]  M. Petri,et al.  Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. , 2013, Arthritis and rheumatism.

[16]  F. Mackay,et al.  Association of serum B cell activating factor from the tumour necrosis factor family (BAFF) and a proliferation-inducing ligand (APRIL) with central nervous system and renal disease in systemic lupus erythematosus , 2013, Lupus.

[17]  C. Jefferies,et al.  Elevated B lymphocyte stimulator levels are associated with increased damage in an Irish systemic lupus erythematosus cohort. , 2013, Rheumatology.

[18]  K. Fairfax,et al.  The BAFF/APRIL system: Emerging functions beyond B cell biology and autoimmunity , 2013, Cytokine & Growth Factor Reviews.

[19]  F. Mackay,et al.  Focus on systemic lupus erythematosus in Indigenous Australians: towards a better understanding of autoimmune diseases , 2013, Internal medicine journal.

[20]  J. Crowley,et al.  Serum B‐cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival , 2012, British journal of haematology.

[21]  X. Qu,et al.  Soluble BAFF-R produced by decidual stromal cells plays an inhibitory role in monocytes and macrophages. , 2012, Reproductive biomedicine online.

[22]  M. Petri,et al.  A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. , 2011, Arthritis and rheumatism.

[23]  M. Petri,et al.  Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial , 2011, The Lancet.

[24]  A. Coles,et al.  B-Cell Reconstitution and BAFF After Alemtuzumab (Campath-1H) Treatment of Multiple Sclerosis , 2009, Journal of Clinical Immunology.

[25]  C. Putterman,et al.  Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis. , 2007, Arthritis and rheumatism.

[26]  Mimi Y. Kim,et al.  Combined oral contraceptives in women with systemic lupus erythematosus. , 2005, The New England journal of medicine.

[27]  D. Gladman,et al.  Systemic lupus erythematosus disease activity index 2000. , 2002, The Journal of rheumatology.

[28]  J. Tschopp,et al.  Mice Transgenic for Baff Develop Lymphocytic Disorders along with Autoimmune Manifestations , 1999, The Journal of experimental medicine.

[29]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.